Análise secundária Post Hoc de estudo randomizado | Rivaroxabam em monoterapia está associado com melhores desfechos comparado à terapia combinada com antiplaquetários em pacientes com fibrilação atrial e doença arterial coronariana estável.

Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial – JAMA Cardiology (gratuito por tempo limitado)

Comentários:

Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease: Does Less Mean More? – JAMA Cardiology (gratuito por tempo limitado)

Rivaroxaban Mono vs. Combo Therapy for Thrombotic and Bleeding Events in AF – American College of Cardiology

Rivaroxaban Monotherapy Linked to Lower Event Risk in Patients with AF, Stable CAD – HCPLive

Comentário no Twitter

In this post-hoc study of the AFIRE RCT, recurrent event analyses showed that rivaroxaban monotherapy was associated with lower risks of total thrombotic and/or bleeding events than rivaroxaban plus antiplatelet therapy in patients with AF and stable CAD. https://t.co/TGwatvlrKR

— JAMA Cardiology (@JAMACardio) June 15, 2022